Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

3.95USD
26 May 2017
Change (% chg)

$-0.05 (-1.25%)
Prev Close
$4.00
Open
$3.90
Day's High
$4.00
Day's Low
$3.90
Volume
47,683
Avg. Vol
69,993
52-wk High
$5.25
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Cancer Genetics files for mixed shelf of up to $100 mln
Thursday, 25 May 2017 04:06pm EDT 

May 25 (Reuters) - Cancer Genetics Inc :Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing.  Full Article

Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Cancer Genetics Inc :Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer.Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay.  Full Article

CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51
Thursday, 11 May 2017 06:23pm EDT 

May 11 (Reuters) - Cancer Genetics Inc :CANCER GENETICS INC ANNOUNCES 15% REVENUE INCREASE IN FIRST QUARTER OF 2017 OVER 2016 ON STRONG ORGANIC GROWTH WHILE CONTINUING ON PATH TO PROFITABILITY.Q1 LOSS PER SHARE $0.51.Q1 REVENUE ROSE 15 PERCENT TO $7.0 MILLION.Q1 ADJUSTED LOSS PER SHARE $0.11.  Full Article

Cancer Genetics and Mendel.ai announce strategic partnership
Monday, 3 Apr 2017 07:00am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care .Cancer Genetics - expect that initial partners will be using Mendel.ai system during Q2 of 2017 with wider rollout through Q3 and Q4 of this year.  Full Article

Cancer Genetic Q4 loss per share $0.15
Thursday, 23 Mar 2017 07:30am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update . Q4 loss per share $0.15 .Q4 revenue rose 32 percent to $7.2 million.  Full Article

Cancer Genetics selected by BeiGene to collaborate on clinical trial services, advance portfolio of Novel Oncology Therapeutics
Wednesday, 7 Dec 2016 07:54am EST 

Cancer Genetics Inc :Cancer Genetics, Inc is selected by BeiGene, Ltd to collaborate on clinical trial services & advance portfolio of Novel Oncology Therapeutics.  Full Article

Cancer Genetics receives New York state approval for Focus::Myeloid NGS-based panel
Wednesday, 17 Aug 2016 07:30am EDT 

Cancer Genetics Inc :Received New York state approval for its Focus::Myeloid NGS-based panel for Myeloid malignancies.  Full Article

Cancer Genetics Q1 revenue rose 39 pct to $6.1 mln
Tuesday, 10 May 2016 04:01pm EDT 

Cancer Genetics Inc : Cancer Genetics Inc announces 39% revenue increase and provides recent company highlights .Q1 revenue rose 39 percent to $6.1 million.  Full Article

Cancer Genetics announces closing of $12 million public offering
Thursday, 12 Nov 2015 09:38pm EST 

Cancer Genetics:Confirmed the closing of its previously announced public offering of 3,000,000 shares of its common stock with five-year warrants to purchase 3,000,000 shares of common stock at an exercise price of $5.00 per share at a combined price to the public of $4.00.Cancer Genetics' gross proceeds from this offering were $12.0 million before deducting underwriting discounts and commissions, as well as other estimated offering expenses payable by Cancer Genetics.Says underwriters were granted a 45-day option to purchase up to an aggregate of 450,000 additional shares of common stock and/or warrants.Says the underwriters' option to purchase additional warrants was exercised and sold today.Joseph Gunnar & Co., LLC and Feltl and Company, Inc. acted as the joint book-running managers for the offering.Axiom Capital Management, Inc. acted as co-manager for the offering.Says net proceeds of the offering are estimated to be approximately $10.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.Cancer Genetics intends to use the net proceeds from the offering for the integration of recent acquisitions; sales and marketing to support new product launches; and to fund contributions to OncoSpire, Cancer Genetics' joint venture with the Mayo Clinic.  Full Article

Cancer Genetics, Inc prices public offering of securities
Friday, 6 Nov 2015 06:45am EST 

Cancer Genetics, Inc:Prices public offering of securities.Says public offering of 3 million common shares priced at $4.00 per share.  Full Article

More From Around the Web

BRIEF-Cancer Genetics files for mixed shelf of up to $100 mln

* Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage: